Multicenter Perspective Study: Clinical Evaluation of the Persona MC With Preservation or Sacrifice of the PCL

Primary endpoint

-Evaluation of the survival of the implant after 5 years of follow-up

Secondary endpoints

Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

The trial will be divided into two parts:

PART A:

the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies

PART B:

the second part will include 3 expansion cohorts of …

VARA (Virtual and Augmented Reality Applications in Rehabilitation): Motor Rehabilitation Protocol With GRAIL for Patients Affected by Hemiparesis

A Study to Evaluate the Safety Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

Secondary objectives:

To characterize pharmacokinetics (PK) of single dose AHCQ in healthy individuals.

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Part 2: Participants aged 12 < 18 will receive;

Mobility Protocol Adapted for Advanced Visually Impaired Subjects

People Retinitis Pigmentosa therefore encounter a large number of difficulties in daily life, specifically for:

This study aims to assess the difficulties in the daily life of subjects with …

Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment

2 march edit9  

CAD/CAM Fixed Retainers vs. Conventional Multistranded Fixed Retainers in Orthodontic Patients. Comparison of Stability Retainer Failure Rate Adverse Effects Cost-effectiveness and Patient Satisfaction. A Randomized Controlled Clinical Trial

ul>

Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of Remdesivir (GS-5734 ) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)

The primary objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of remdesivir (RDV) in participants with laboratory-confirmed coronavirus disease 2019 (COVID-19) aged 0 days to < 18 years.